Sponsor Pipeline

Guardant Health, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
3
Recruiting
9
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-08 NCT06880055
Shield Post-Approval Study Protocol		 Trial sites expanded: 56 -> 69 locations
Active Trials by Phase
Not specified
6
Active Trials
NCT IDTitleConditionStatus
Not specified
NCT05059444 ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation Bladder Carcinoma Recruiting
NCT05935384 SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation Non-small Cell Lung Cancer Recruiting
NCT06880055 Shield Post-Approval Study Protocol Colo-rectal Cancer Recruiting
NCT04136002 Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode Colorectal Cancer Active, Not Recruiting
NCT07620535 Decision Counseling and Follow-up for Shield+ Patients Colo-rectal Cancer Not Yet Recruiting
NCT05117840 Screening for High Frequency Malignant Disease Lung Cancer Active, Not Recruiting
Disease Areas
Colorectal Cancer (4) Lung Cancer (3) Non-Small Cell Lung Cancer (NSCLC) (2) Breast Cancer (2) Kidney Cancer (1) Ovarian Cancer (1) Endometrial Cancer (1) Melanoma (1) Esophageal Cancer (1)
Get alerts when Guardant Health, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free